Erica Ollmann Saphire

List of Publications by Year in Descending Order

153 papers	13,750 citations	50 h-index	116 g-index
175 ext. papers	17,611 ext. citations	16 avg, IF	6.51 L-index

#	Paper	IF	Citations
153	A Manhattan Project against COVID.. *FASEB Journal*, **2022**, 36, e22117	0.9	
152	Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.. *MAbs*, **2022**, 14, 2002236	6.6	2
151	Stopping pandemics before they start: Lessons learned from SARS-CoV-2.. *Science*, **2022**, 375, 1133-1139	33.3	8
150	Asymmetric and non-stoichiometric glycoprotein recognition by two distinct antibodies results in broad protection against ebolaviruses.. *Cell*, **2022**, 185, 995-1007.e18	56.2	7
149	Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo.. *PLoS Neglected Tropical Diseases*, **2022**, 16, e0010167	4.8	1
148	Functional interactomes of the Ebola virus polymerase identified by proximity proteomics in the context of viral replication.. *Cell Reports*, **2022**, 38, 110544	10.6	1
147	CD164 is a host factor for lymphocytic choriomeningitis virus entry.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2119676119	11.5	1
146	mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions.. *Science Translational Medicine*, **2022**, 14, eabm2311	17.5	11
145	Inducing broad-based immunity against viruses with pandemic potential.. *Immunity*, **2022**, 55, 738-748	32.3	0
144	Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies. *Cell Reports*, **2022**, 39, 110841	10.6	2
143	SARS-CoV-2 infection generates tissue-localized immunological memory in humans. *Science Immunology*, **2021**, 6, eabl9105	28	33
142	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. *Immunity*, **2021**, 54, 815-828.e5	32.3	7
141	Cellular mRNA triggers structural transformation of Ebola virus matrix protein VP40 to its essential regulatory form. *Cell Reports*, **2021**, 35, 108986	10.6	5
140	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. *Cell Reports*, **2021**, 36, 109452	10.6	25
139	Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. *Science Translational Medicine*, **2021**, 13,	17.5	6
138	Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. *Frontiers in Immunology*, **2021**, 12, 706757	8.4	0
137	Analysis of Oligomeric and Glycosylated Proteins by Size-Exclusion Chromatography Coupled with Multiangle Light Scattering. *Methods in Molecular Biology*, **2021**, 2271, 343-359	1.4	0

136	Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M vaccination **2021**,		16
135	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*, **2021**, 371,	33.3	1183
134	Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry. *PLoS Pathogens*, **2021**, 17, e1009312	7.6	5
133	Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination **2021**,		6
132	Prominent Neutralizing Antibody Response Targeting the Glycoprotein Subunit Interface Elicited by Immunization. *Journal of Virology*, **2021**,	6.6	4
131	Novel attempts launched toward universal Sarbecovirus vaccine. *Cell Research*, **2021**, 31, 1226-1227	24.7	
130	Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles **2021**,		8
129	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. *Cell Reports Medicine*, **2021**, 2, 100405	18	34
128	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. *Science*, **2021**, 374, 472-478	33.3	72
127	Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*, **2020**, 182, 812-827.e19	56.2	2322
126	Reporter Assays for Ebola Virus Nucleoprotein Oligomerization, Virion-Like Particle Budding, and Minigenome Activity Reveal the Importance of Nucleoprotein Amino Acid Position 111. *Viruses*, **2020**, 12,	6.2	3
125	Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. *Immunity*, **2020**, 52, 388-403.e12	32.3	42
124	A Vaccine against Ebola Virus. *Cell*, **2020**, 181, 6	56.2	35
123	Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies. *Cell Host and Microbe*, **2020**, 27, 976-991.e11	23.4	29
122	Ebola and Marburg virus matrix layers are locally ordered assemblies of VP40 dimers. *ELife*, **2020**, 9,	8.9	9
121	Author response: Ebola and Marburg virus matrix layers are locally ordered assemblies of VP40 dimers **2020**,		2
120	Spiking Pandemic Potential: Structural and Immunological Aspects of SARS-CoV-2. *Trends in Microbiology*, **2020**, 28, 605-618	12.4	21
119	Lifted Up from Lockdown. *Cell*, **2020**, 183, 1-3	56.2	55

118	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. *Cell*, **2020**, 183, 996-1012.e19	56.2	711
117	Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. *Scientific Reports*, **2020**, 10, 16030	4.9	6
116	SnapShot: Enveloped Virus Entry. *Cell*, **2020**, 182, 786-786.e1	56.2	15
115	Diverse Morphology and Structural Features of Old and New World Hantaviruses. *Viruses*, **2019**, 11,	6.2	10
114	A glimpse into immune responses evolving against Ebola virus. *Nature Medicine*, **2019**, 25, 1470-1471	50.5	5
113	Cryo-EM structure of the Ebola virus nucleoprotein-RNA complex. *Acta Crystallographica Section F, Structural Biology Communications*, **2019**, 75, 340-347	1.1	8
112	Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk. *Nature Communications*, **2019**, 10, 1788	17.4	17
111	Achieving cross-reactivity with pan-ebolavirus antibodies. *Current Opinion in Virology*, **2019**, 34, 140-148	7.5	15
110	Structural basis of broad ebolavirus neutralization by a human survivor antibody. *Nature Structural and Molecular Biology*, **2019**, 26, 204-212	17.6	20
109	A Conserved Basic Patch and Central Kink in the Nipah Virus Phosphoprotein Multimerization Domain Are Essential for Polymerase Function. *Structure*, **2019**, 27, 660-668.e4	5.2	8
108	Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. *Journal of Virology*, **2019**, 93,	6.6	13
107	Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization. *Cell*, **2019**, 178, 1004-1015.e14	56.2	16
106	Antibody therapy for Lassa fever. *Current Opinion in Virology*, **2019**, 37, 97-104	7.5	9
105	Sudan Ebolavirus VP35-NP Crystal Structure Reveals a Potential Target for Pan-Filovirus Treatment. *MBio*, **2019**, 10,	7.8	4
104	Single Amino Acid Substitutions Dramatically Shift Equilibria of Physiologically Relevant Alternate Protein Assemblies. *FASEB Journal*, **2019**, 33, 779.20	0.9	
103	Structural Characterization of Pan-Ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein. *Journal of Infectious Diseases*, **2019**, 219, 415-419	7	12
102	Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. *Scientific Reports*, **2018**, 8, 5939	4.9	26
101	A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine. *Journal of Biological Chemistry*, **2018**, 293, 3335-3349	5.4	20

100	The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding. *Cell Host and Microbe*, **2018**, 23, 101-109.e4	23.4	25
99	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. *Immunity*, **2018**, 49, 363-374.e10	32.3	47
98	Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. *Nature Microbiology*, **2018**, 3, 670-677	26.6	47
97	Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses. *MSphere*, **2018**, 3,	5	27
96	Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors. *Cell Reports*, **2018**, 24, 1816-1829	10.6	5
95	Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors. *Journal of Infectious Diseases*, **2018**, 218, 1929-1936	7	13
94	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. *Cell Host and Microbe*, **2018**, 24, 221-233.e5	23.4	121
93	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. *Cell*, **2018**, 174, 938-952.e13	56.2	126
92	In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. *Cell Reports*, **2018**, 25, 1982-1993.e4	10.6	20
91	Antibody-mediated protection against Ebola virus. *Nature Immunology*, **2018**, 19, 1169-1178	19.1	90
90	Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope. *MBio*, **2018**, 9,	7.8	24
89	Lassa virus glycoprotein: stopping a moving target. *Current Opinion in Virology*, **2018**, 31, 52-58	7.5	18
88	The structural basis for filovirus neutralization by monoclonal antibodies. *Current Opinion in Immunology*, **2018**, 53, 196-202	7.8	12
87	Structural basis for antibody-mediated neutralization of Lassa virus. *Science*, **2017**, 356, 923-928	33.3	119
86	Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein. *Virology*, **2017**, 512, 161-171	3.6	15
85	How to turn competitors into collaborators. *Nature*, **2017**, 541, 283-285	50.4	3
84	Filovirus Structural Biology: The Molecules in the Machine. *Current Topics in Microbiology and Immunology*, **2017**, 411, 381-417	3.3	15
83	Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein. *Structure*, **2017**, 25, 1820-1828.e2	5.2	4

82	Crystal Structure of the Marburg Virus VP35 Oligomerization Domain. *Journal of Virology*, **2017**, 91,	6.6	32
81	Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. *MBio*, **2016**, 7, e02154-15	7.8	72
80	More than Meets the Eye: Hidden Structures in the Proteome. *Annual Review of Virology*, **2016**, 3, 373-386	4.6	8
79	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. *Nature Microbiology*, **2016**, 1, 16128	26.6	78
78	Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?. *Trends in Microbiology*, **2016**, 24, 684-686	12.4	17
77	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. *Cell Reports*, **2016**, 15, 1514-1526	10.6	68
76	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. *Cell*, **2016**, 164, 392-405	56.2	126
75	Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. *Science* , **2016**, 351, 1078-83	33.3	153
74	Crystal Structure of Marburg Virus VP40 Reveals a Broad, Basic Patch for Matrix Assembly and a Requirement of the N-Terminal Domain for Immunosuppression. *Journal of Virology*, **2016**, 90, 1839-48	6.6	27
73	Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z. *Journal of Virology*, **2016**, 90, 4556-62	6.6	18
72	Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. *Journal of Virology*, **2016**, 90, 266-78	6.6	78
71	The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis. *PLoS Pathogens*, **2016**, 12, e1005937	7.6	45
70	An Outbreak of Ebola Virus Disease in the Lassa Fever Zone. *Journal of Infectious Diseases*, **2016**, 214, S110-S121	7	25
69	Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. *Nature Communications*, **2016**, 7, 11544	17.4	99
68	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. *Science Translational Medicine*, **2016**, 8, 329ra33	17.5	62
67	Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV. *Nature Structural and Molecular Biology*, **2016**, 23, 513-521	17.6	47
66	Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. *Journal of Infectious Diseases*, **2016**, 214, S210-S217	7	25
65	A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses. *Science*, **2016**, 354, 350-354	33.3	86

64	High-resolution Crystal Structure of Dimeric VP40 From Sudan ebolavirus. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S167-71	7	6
63	New Advances in the Effort against Ebola. *Cell Host and Microbe*, **2015**, 17, 545-7	23.4	3
62	Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 Complex. *Cell Reports*, **2015**, 12, 140-149	10.6	89
61	Swift antibodies to counter emerging viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 10082-3	11.5	4
60	Potent Antibody Protection against an Emerging Alphavirus Threat. *Cell*, **2015**, 163, 1053-1054	56.2	5
59	Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. *PLoS Pathogens*, **2015**, 11, e1005016	7.6	27
58	Mechanism of human antibody-mediated neutralization of Marburg virus. *Cell*, **2015**, 160, 893-903	56.2	114
57	Structural basis for Marburg virus neutralization by a cross-reactive human antibody. *Cell*, **2015**, 160, 904-912	56.2	91
56	Development of Prototype Filovirus Recombinant Antigen Immunoassays. *Journal of Infectious Diseases*, **2015**, 212 Suppl 2, S359-67	7	26
55	Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak. *Viral Immunology*, **2015**, 28, 19-31	1.7	29
54	Functional Studies of Ebola Virus Matrix Protein VP40. *FASEB Journal*, **2015**, 29, 886.3	0.9	
53	Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. *Archives of Virology*, **2014**, 159, 821-30	2.6	72
52	Complement is activated by IgG hexamers assembled at the cell surface. *Science*, **2014**, 343, 1260-3	33.3	424
51	Structures of protective antibodies reveal sites of vulnerability on Ebola virus. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 17182-7	11.5	146
50	Structure of the LCMV nucleoprotein provides a template for understanding arenavirus replication and immunosuppression. *Acta Crystallographica Section D: Biological Crystallography*, **2014**, 70, 1764-9		10
49	Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. *Archives of Virology*, **2014**, 159, 1229-37	2.6	52
48	Crystal structure of the nipah virus phosphoprotein tetramerization domain. *Journal of Virology*, **2014**, 88, 758-62	6.6	48
47	Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. *Viruses*, **2014**, 6, 3663-82	6.2	44

46	Lassa fever in post-conflict sierra leone. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2748	4.8	126
45	Structural insights into RNA encapsidation and helical assembly of the Toscana virus nucleoprotein. *Nucleic Acids Research*, **2014**, 42, 6025-37	20.1	26
44	Crystal structure of Marburg virus VP24. *Journal of Virology*, **2014**, 88, 5859-63	6.6	17
43	Structure of the Reston ebolavirus VP30 C-terminal domain. *Acta Crystallographica Section F, Structural Biology Communications*, **2014**, 70, 457-60	1.1	9
42	Structural rearrangement of ebola virus VP40 begets multiple functions in the virus life cycle. *Cell*, **2013**, 154, 763-74	56.2	155
41	An update on the use of antibodies against the filoviruses. *Immunotherapy*, **2013**, 5, 1221-33	3.8	31
40	Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism. *Journal of Virology*, **2013**, 87, 10385-8	6.6	38
39	Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma. *Blood*, **2013**, 122, 375-375	2.2	1
38	Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. *Current Opinion in Virology*, **2012**, 2, 151-6	7.5	21
37	Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein. *ChemBioChem*, **2012**, 13, 2549-57	3.8	26
36	Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease. *PLoS ONE*, **2012**, 7, e44211	3.7	42
35	The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. *PLoS Pathogens*, **2012**, 8, e1002550	7.6	99
34	Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. *PLoS Pathogens*, **2012**, 8, e1002916	7.6	54
33	Structural basis for differential neutralization of ebolaviruses. *Viruses*, **2012**, 4, 447-70	6.2	57
32	The ebolavirus VP24 interferon antagonist: know your enemy. *Virulence*, **2012**, 3, 440-5	4.7	37
31	Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. *Journal of Virology*, **2012**, 86, 364-72	6.6	110
30	Structure of an antibody in complex with its mucin domain linear epitope that is protective against Ebola virus. *Journal of Virology*, **2012**, 86, 2809-16	6.6	40
29	Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3Pto 5Pexonuclease activity essential for immune suppression. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 2396-401	11.5	188

28	Measles virus fusion shifts into gear. *Nature Structural and Molecular Biology*, **2011**, 18, 115-6	17.6	8
27	A shared structural solution for neutralizing ebolaviruses. *Nature Structural and Molecular Biology*, **2011**, 18, 1424-7	17.6	101
26	Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 19365-70	11.5	93
25	Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. *PLoS Neglected Tropical Diseases*, **2011**, 5, e1395	4.8	57
24	Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 314-9	11.5	106
23	Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. *Current Opinion in Structural Biology*, **2009**, 19, 408-17	8.1	50
22	Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. *Acta Crystallographica Section D: Biological Crystallography*, **2009**, 65, 1162-80		24
21	An efficient platform for screening expression and crystallization of glycoproteins produced in human cells. *Nature Protocols*, **2009**, 4, 592-604	18.8	40
20	Ebolavirus glycoprotein structure and mechanism of entry. *Future Virology*, **2009**, 4, 621-635	2.4	176
19	Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. *Nature*, **2008**, 454, 177-82	50.4	538
18	Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain. *Journal of Molecular Biology*, **2008**, 375, 202-16	6.5	47
17	Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. *Journal of Molecular Biology*, **2007**, 369, 696-709	6.5	63
16	Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. *Journal of Virology*, **2006**, 80, 5168-78	6.6	353
15	Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. *Journal of Virology*, **2003**, 77, 5863-76	6.6	90
14	Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. *Virology*, **2003** , 315, 159-73	3.6	46
13	Crystal structure of an intact human IgG: antibody asymmetry, flexibility, and a guide for HIV-1 vaccine design. *Advances in Experimental Medicine and Biology*, **2003**, 535, 55-66	3.6	32
12	Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. *Journal of Virology*, **2003**, 77, 642-58	6.6	225
11	The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. *Advances in Experimental Medicine and Biology*, **2003**, 535, 205-18	3.6	55

10	The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. *Journal of Virology*, **2002**, 76, 7306-21	6.6	617
9	Contrasting IgG structures reveal extreme asymmetry and flexibility. *Journal of Molecular Biology*, **2002**, 319, 9-18	6.5	209
8	Structure-based drug design. *IDrugs: the Investigational Drugs Journal*, **2002**, 5, 658-61		
7	Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. *Acta Crystallographica Section D: Biological Crystallography*, **2001**, 57, 168-71		37
6	Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. *Science*, **2001**, 293, 1155-9	33.3	764
5	Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. *Journal of Virology*, **2001**, 75, 10892-905	6.6	680
4	gp120: Biologic aspects of structural features. *Annual Review of Immunology*, **2001**, 19, 253-74	34.7	215
3	Structural Basis of Broad Ebolavirus Neutralization by a Human Survivor Antibody		1
2	Structure of the Ebola virus nucleoprotein–RNA complex		1
1	Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity		9